Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04936308




Registration number
NCT04936308
Ethics application status
Date submitted
16/06/2021
Date registered
23/06/2021
Date last updated
22/05/2024

Titles & IDs
Public title
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Scientific title
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent
Secondary ID [1] 0 0
2021-000482-32
Secondary ID [2] 0 0
CR109039
Universal Trial Number (UTN)
Trial acronym
SOLSTICE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Psoriatic 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab
Treatment: Drugs - Placebo

Experimental: Group 1: Guselkumab and Placebo - Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.

Experimental: Group 2: Guselkumab - Participants will receive guselkumab SC.

Experimental: Group 3: Placebo Followed by Guselkumab - Participants will receive placebo SC and will cross over to receive guselkumab SC.


Treatment: Drugs: Guselkumab
Participants will receive guselkumab as SC injection.

Treatment: Drugs: Placebo
Participants will receive matching placebo as SC injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 20 Response at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Percentage of Participants who Achieve a Psoriasis Response of IGA Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 at Baseline
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percentage of Participants who Achieve PASI 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Change From Baseline in HAQ-DI Score at Week 24
Timepoint [3] 0 0
Baseline and Week 24
Secondary outcome [4] 0 0
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Timepoint [4] 0 0
Baseline and Week 24
Secondary outcome [5] 0 0
Change From Baseline in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score at Week 24
Timepoint [5] 0 0
Baseline and Week 24
Secondary outcome [6] 0 0
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
Timepoint [6] 0 0
Week 24
Secondary outcome [7] 0 0
Percentage of Participants who Achieve ACR 20 Response at Week 16
Timepoint [7] 0 0
Week 16
Secondary outcome [8] 0 0
Percentage of Participants who Achieve ACR 50 Response at Week 16
Timepoint [8] 0 0
Week 16
Secondary outcome [9] 0 0
Percentage of Participants who Achieve ACR 50 Response at Week 24
Timepoint [9] 0 0
Week 24
Secondary outcome [10] 0 0
Percentage of Participants who Achieve ACR 70 Response at Week 24
Timepoint [10] 0 0
Week 24
Secondary outcome [11] 0 0
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Reasonably Related AEs, as a Measure of Safety and Tolerability
Timepoint [11] 0 0
Up to 112 weeks
Secondary outcome [12] 0 0
Percentage of Participants With AEs leading to Discontinuation of Study Intervention
Timepoint [12] 0 0
Up to 112 weeks
Secondary outcome [13] 0 0
Percentage of Participants With Infections
Timepoint [13] 0 0
Up to 112 weeks
Secondary outcome [14] 0 0
Percentage of Participants With Injection-site Reactions
Timepoint [14] 0 0
Up to 100 weeks
Secondary outcome [15] 0 0
Percentage of Participants With Change from Baseline in Clinical Laboratory Abnormalities
Timepoint [15] 0 0
Up to 112 weeks
Secondary outcome [16] 0 0
Percentage of participants With Laboratory Abnormalities With Maximum Toxicity Grades as per Common Terminology Criteria for Adverse Events (CTCAE) Toxicity
Timepoint [16] 0 0
Up to 112 weeks
Secondary outcome [17] 0 0
Serum Guselkumab Concentration
Timepoint [17] 0 0
Up to 112 weeks
Secondary outcome [18] 0 0
Percentage of Participants With Anti-guselkumab Antibodies
Timepoint [18] 0 0
Up to 112 weeks

Eligibility
Key inclusion criteria
- Have a diagnosis of active psoriatic arthritis (PsA) for at least 6 months before the
first administration of study agent and meet Classification criteria for Psoriatic
Arthritis (CASPAR) at screening

- Have active PsA as defined by: at least 3 swollen joints and at least 3 tender joints
at screening and at baseline; and C-reactive protein (CRP) greater than or equal to
(>=) 0.3 milligrams per deciliter (mg/dL) at screening from the central laboratory

- Have at least one of the following PsA subsets: distal interphalangeal joint
involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric
peripheral arthritis, or spondylitis with peripheral arthritis

- Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeters
(cm) diameter and/or nail changes consistent with psoriasis, or documented history of
plaque psoriasis

- Have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha
(TNF alpha) therapy, defined as presence of active PsA despite previous treatment with
one prior anti-TNF alpha agent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has other inflammatory diseases that might confound the evaluations of benefit of
guselkumab therapy in the treatment of PsA, including but not limited to rheumatoid
arthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemic
lupus erythematosus, or Lyme disease

- Has received more than 1 prior anti-tumor necrosis factor (TNF) alpha agent (or
biosimilars)

- Has ever received Janus kinase (JAK) inhibitor including but not limited to
tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any
other investigational JAK inhibitor

- Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6
thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4
weeks of the first administration of study intervention

- Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients

- Has a history of chronic or recurrent infectious disease, including but not limited to
chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent
urinary tract infection (example, recurrent pyelonephritis or chronic non-remitting
cystitis), fungal infection (example, mucocutaneous candidiasis), or open, draining,
or infected skin wounds or ulcers

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
7/09/2026
Actual
Sample size
Target
450
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Southern Clinical Research - Hobart
Recruitment hospital [2] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 0 0
Skin Health Institute Inc. - Melbourne
Recruitment hospital [4] 0 0
Eastern Health - Box Hill Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
7000 - Hobart
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
3053 - Melbourne
Recruitment postcode(s) [4] 0 0
3128 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
United States of America
State/province [22] 0 0
West Virginia
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad Autonoma de Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciudad Autónoma de Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciudad de Mendoza
Country [27] 0 0
Argentina
State/province [27] 0 0
San Miguel De Tucuman
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Pleven
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Plovdiv
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Ruse
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sfia
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Czechia
State/province [33] 0 0
Breclav
Country [34] 0 0
Czechia
State/province [34] 0 0
Hlucin
Country [35] 0 0
Czechia
State/province [35] 0 0
Ostrava
Country [36] 0 0
Czechia
State/province [36] 0 0
Pardubice
Country [37] 0 0
Czechia
State/province [37] 0 0
Praha 2
Country [38] 0 0
Czechia
State/province [38] 0 0
Uherske Hradiste
Country [39] 0 0
Czechia
State/province [39] 0 0
Zlin
Country [40] 0 0
Hungary
State/province [40] 0 0
Budapest
Country [41] 0 0
Hungary
State/province [41] 0 0
Debrecen
Country [42] 0 0
Hungary
State/province [42] 0 0
Gyula
Country [43] 0 0
Hungary
State/province [43] 0 0
Kistarcsa
Country [44] 0 0
Hungary
State/province [44] 0 0
Szeged
Country [45] 0 0
Hungary
State/province [45] 0 0
Szekesfehervar
Country [46] 0 0
Hungary
State/province [46] 0 0
Veszprem
Country [47] 0 0
Israel
State/province [47] 0 0
Haifa
Country [48] 0 0
Israel
State/province [48] 0 0
Hifa
Country [49] 0 0
Israel
State/province [49] 0 0
Kfar-Sava
Country [50] 0 0
Israel
State/province [50] 0 0
Ramat Gan
Country [51] 0 0
Malaysia
State/province [51] 0 0
Batu Caves
Country [52] 0 0
Malaysia
State/province [52] 0 0
George Town
Country [53] 0 0
Malaysia
State/province [53] 0 0
Ipoh
Country [54] 0 0
Malaysia
State/province [54] 0 0
Seremban
Country [55] 0 0
Poland
State/province [55] 0 0
Bytom
Country [56] 0 0
Poland
State/province [56] 0 0
Elblag
Country [57] 0 0
Poland
State/province [57] 0 0
Krakow
Country [58] 0 0
Poland
State/province [58] 0 0
Lodz
Country [59] 0 0
Poland
State/province [59] 0 0
Nadarzyn
Country [60] 0 0
Poland
State/province [60] 0 0
Nowa Sol
Country [61] 0 0
Poland
State/province [61] 0 0
Poznan
Country [62] 0 0
Poland
State/province [62] 0 0
Swidnik
Country [63] 0 0
Poland
State/province [63] 0 0
Warsaw
Country [64] 0 0
Poland
State/province [64] 0 0
Warszawa
Country [65] 0 0
Poland
State/province [65] 0 0
Wroclaw
Country [66] 0 0
Puerto Rico
State/province [66] 0 0
San Juan
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Barnaul
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Chelyabinsk
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Kemerovo
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Korolev
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Krasnodar
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Krasnoyarsk
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Moscow
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Orenburg
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Rostov
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Saratov
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Smolensk
Country [78] 0 0
Russian Federation
State/province [78] 0 0
St. Petersburg
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Tolyatti
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Tula
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Ufa
Country [82] 0 0
Spain
State/province [82] 0 0
Barakaldo
Country [83] 0 0
Spain
State/province [83] 0 0
Madrid
Country [84] 0 0
Spain
State/province [84] 0 0
Málaga
Country [85] 0 0
Spain
State/province [85] 0 0
Santiago de Compostela
Country [86] 0 0
Spain
State/province [86] 0 0
Sevilla
Country [87] 0 0
Spain
State/province [87] 0 0
Valencia
Country [88] 0 0
Turkey
State/province [88] 0 0
Adana
Country [89] 0 0
Turkey
State/province [89] 0 0
Ankara
Country [90] 0 0
Turkey
State/province [90] 0 0
Antalya
Country [91] 0 0
Turkey
State/province [91] 0 0
Bursa
Country [92] 0 0
Turkey
State/province [92] 0 0
Denizli
Country [93] 0 0
Turkey
State/province [93] 0 0
Eskisehir
Country [94] 0 0
Turkey
State/province [94] 0 0
Istanbul
Country [95] 0 0
Turkey
State/province [95] 0 0
Kocaeli
Country [96] 0 0
Turkey
State/province [96] 0 0
Konya
Country [97] 0 0
Ukraine
State/province [97] 0 0
Cherkasy
Country [98] 0 0
Ukraine
State/province [98] 0 0
Kharkiv
Country [99] 0 0
Ukraine
State/province [99] 0 0
Khmelnytsky
Country [100] 0 0
Ukraine
State/province [100] 0 0
Kryvyi Rih
Country [101] 0 0
Ukraine
State/province [101] 0 0
Kyiv
Country [102] 0 0
Ukraine
State/province [102] 0 0
Lutsk
Country [103] 0 0
Ukraine
State/province [103] 0 0
Odessa
Country [104] 0 0
Ukraine
State/province [104] 0 0
Poltava
Country [105] 0 0
Ukraine
State/province [105] 0 0
Vinnytsya
Country [106] 0 0
Ukraine
State/province [106] 0 0
Zaporizhzhya

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants
with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a
prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of
PsA.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04936308
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
Participate-In-This-Study@its.jnj.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04936308